Eupraxia Pharmaceuticals Inc.
EPRXF
Other OTC3.04
USD
-0.20
- -
ISIN
CA29842P1053
Return %
Stock
S&P500
1Y
-31.99
26.53
3Y
9.00
76.60
5Y
9.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James A. Helliwell FRCPC,
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2067 Cadboro Bay Road Victoria BC Canada V8R 5G4
- IPO Date
- Aug 3, 2021
- Website
- eupraxiapharma.com
- Similar Companies
- Business
- Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company specializing in the development of locally delivered, extended-release pharmaceutical products utilizing its proprietary Diffusphere™ technology platform. The company’s core product candidates include EP-104GI, an injectable formulation designed for the treatment of eosinophilic esophagitis (EoE), which delivers targeted, sustained anti-inflammatory therapy directly to the esophageal tissue to improve symptom control and tissue health. Eupraxia also develops EP-104IAR, a long-acting injectable therapy for pain due to knee osteoarthritis, along with a pipeline of early and later-stage long-acting formulations addressing inflammatory joint conditions, oncology, post-surgical pain, and infections. These products aim to enhance the safety, efficacy, tolerability, and duration of effect beyond currently approved drugs by leveraging precision, localized drug delivery. Founded in 2015 and headquartered in Vancouver, Canada, Eupraxia operates primarily in North America with ongoing clinical trials targeting indications with large unmet medical needs. The company’s innovative Diffusphere technology uses polymer-based microspheres to enable controlled, extended drug release directly at the disease site, potentially enabling fewer adverse events and improved patient outcomes. Recent major developments include the announcement of positive 52-week clinical data from the Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis, showing durable symptom remission and tissue improvements. Eupraxia completed patient enrollment for its Phase 2b trial of EP-104IAR in knee osteoarthritis, which met its primary endpoint and multiple secondary endpoints, affirming its therapeutic potential. The company also secured $80.5 million in a public offering to support ongoing clinical development and pipeline expansion, with expectations to report topline Phase 2b data for EP-104GI in Q3 2026. Strategic plans include expanding indications for EP-104GI to other gastrointestinal inflammatory diseases and developing new candidates in inflammatory and oncology fields. Additionally, Eupraxia recently appointed Paul Brennan as Chief Business Officer to strengthen its commercial capabilities. Eupraxia Pharmaceuticals is positioned at the intersection of biotechnology and drug delivery innovation, targeting high-value chronic inflammatory and musculoskeletal markets with its locally acting, extended-release therapeutic candidates aimed at improving quality of life for patients worldwide. The company’s ongoing clinical programs and financing efforts underpin its trajectory toward commercialization and broader therapeutic reach.
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Up 3.6% – What’s Next?
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results